Clinical Trial Update: ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 study ARTEMIS-003 evaluating HS-20093 in metastatic castration-resistant prostate cancer and advanced solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• HS-20093

Snippet

Sponsor: Hansoh BioMedical R&D Company | Conditions: Metastasis Castration Resistant Prostate Cancer(mCRPC) | Phase 2 | Status: RECRUITING